驱动蛋白家族成员20A对肺腺癌预后、免疫浸润及药物反应的预测作用  

Predictive effect of kinesin family member 20A on prognosis,immune infiltration and drug response in lung adenocarcinoma

作　　者：罗宏 丁巍巍 井海亮 李梦莲 LUO Hong;DING Weiwei;JING Hailiang;LI Menglian(Department of Oncology,Yancheng Branch of Nanjing Drum Tower Hospital,Jiangsu Province,Yancheng224000,China;Department of Respiratory Medicine,Yancheng Branch of Nanjing Drum Tower Hospital,Jiangsu Province,Yancheng224000,China;Department of Traditional Chinese Medicine Oncology,Yancheng Branch of Nanjing Drum Tower Hospital,Jiangsu Province,Yancheng224000,China)

机构地区：[1]南京鼓楼医院盐城分院肿瘤科,江苏盐城224000 [2]南京鼓楼医院盐城分院呼吸内科,江苏盐城224000 [3]南京鼓楼医院盐城分院中医肿瘤科,江苏盐城224000

出　　处：《中国当代医药》2025年第1期4-11,共8页China Modern Medicine

摘　　要：目的探讨驱动蛋白家族成员20A(KIF20A)在肺腺癌(LUAD)中的表达及其对患者预后、免疫浸润和药物反应的预测价值,为LUAD患者提供更多可行的治疗策略。方法收集来自5个独立公共数据集的LUAD、正常肺组织的样本及相关临床数据,利用生物信息学工具分析KIF20A在LUAD及正常肺组织中的表达差异,通过生存分析曲线及meta模型评估KIF20A表达与预后的相关性;同时探究KIF20A与免疫细胞浸润的关系及调控的生物学通路,并结合药敏数据库、免疫表型评分(IPS)分析KIF20A对常用化疗、靶向及免疫药物的敏感性。结果LUAD样本组织中KIF20A表达量高于正常肺组织,差异有统计学意义(P<0.001),且其高表达与肿瘤淋巴结转移相关(N_(0)+N_(1) vs.N_(2)+N_(3),P<0.001);各数据集中KIF20A高表达组患者的总生存率(OS)均差于低表达组患者,差异有统计学意义(P<0.05);纳入1636例LUAD样本的meta分析显示KIF20A的高表达与患者的死亡风险升高有关(OR=1.96,95%CI:1.59~2.43,P<0.05);高、低KIF20A表达分组的肿瘤样本在生物学功能、免疫细胞浸润上比较,差异有统计学意义(P<0.05);KIF20A高表达组对多种常见化疗药物(如紫杉醇和吉西他滨)、靶向药物(如吉非替尼、厄洛替尼)的敏感性高于低表达组,而对免疫药物的反应要差于低表达组,差异有统计学意义(P<0.05)。结论KIF20A可通过调控免疫浸润和药物反应来影响患者的预后,其可作为LUAD潜在的预后标志物和治疗靶点。Objective To explore the expression of kinesin family member 20A(KIF20A)in lung adenocarcinoma(LUAD)and its predictive value for prognosis,immune infiltration and drug response of patients,to provide more feasible treatment strategies for LUAD patients.Methods Samples of LUAD and normal lung tissues,along with related clinical data,were collected from five independent public datasets.Bioinformatics tools were used to analyze the expression differences of KIF20A between LUAD and normal lung tissues.The correlation between KIF20A expression and prognosis was evaluated through survival analysis curves and meta-analysis models.The relationship between KIF20A and immune cell infiltration,as well as the regulated biological pathways were explored.Drug sensitivity databases and immunophenoscore(IPS)analysis were used to assess the sensitivity of KIF20A to commonly used chemotherapeutic,targeted,and immunotherapeutic drugs.Results In LUAD tissue samples,KIF20A expression was higher compared to normal lung tissues,with statistically significant differences(P<0.05),and its high expression was associated with tumor lymph node metastasis(N_(0)+N_(1) vs.N_(2)+N_(3),P<0.001).The overall survival(OS)of KIF20A high expression group was worse than that of low expression group in each dataset,and the differences were statistically significant(P<0.05).Meta-analysis of 1636 LUAD samples showed that high KIF20A expression was associated with increased mortality risk(OR=1.96,95%CI:1.59-2.43,P<0.05).There were significant differences in biological function and immune cell infiltration between tumor samples with high and low KIF20A expression(P<0.05).The sensitivity of KIF20A high expression group to a variety of common chemotherapy drugs(such as Paclitaxel and Gemcitabine)and targeted drugs(such as Gefitinib and Erlotinib)were higher than those of low expression group,while the response to immune drugs was worse than that of low expression group,and the differences were statistically significant(P<0.05).Conclusion KIF20A can affect the

关 键 词：肺腺癌 驱动蛋白 肿瘤微环境 药物耐药性 生物标志物 

分 类 号：R734.2[医药卫生—肿瘤]